442 related articles for article (PubMed ID: 33378947)
1. The gut microbiome-bile acid axis in hepatocarcinogenesis.
Wu L; Feng J; Li J; Yu Q; Ji J; Wu J; Dai W; Guo C
Biomed Pharmacother; 2021 Jan; 133():111036. PubMed ID: 33378947
[TBL] [Abstract][Full Text] [Related]
2. Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC.
Sydor S; Best J; Messerschmidt I; Manka P; Vilchez-Vargas R; Brodesser S; Lucas C; Wegehaupt A; Wenning C; Aßmuth S; Hohenester S; Link A; Faber KN; Moshage H; Cubero FJ; Friedman SL; Gerken G; Trauner M; Canbay A; Bechmann LP
Clin Transl Gastroenterol; 2020 Mar; 11(3):e00131. PubMed ID: 32352707
[TBL] [Abstract][Full Text] [Related]
3. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.
Jiang JW; Chen XH; Ren Z; Zheng SS
Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):19-27. PubMed ID: 30527903
[TBL] [Abstract][Full Text] [Related]
4. The Role of the Gut Microbiota in Bile Acid Metabolism.
Ramírez-Pérez O; Cruz-Ramón V; Chinchilla-López P; Méndez-Sánchez N
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s15-s20. PubMed ID: 29080339
[TBL] [Abstract][Full Text] [Related]
5. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation.
Degirolamo C; Modica S; Vacca M; Di Tullio G; Morgano A; D'Orazio A; Kannisto K; Parini P; Moschetta A
Hepatology; 2015 Jan; 61(1):161-70. PubMed ID: 24954587
[TBL] [Abstract][Full Text] [Related]
6. Bile acids and the gut microbiome.
Ridlon JM; Kang DJ; Hylemon PB; Bajaj JS
Curr Opin Gastroenterol; 2014 May; 30(3):332-8. PubMed ID: 24625896
[TBL] [Abstract][Full Text] [Related]
7. Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma.
Song Y; Lau HC; Zhang X; Yu J
Cancer Biol Med; 2023 Dec; 21(2):144-62. PubMed ID: 38148326
[TBL] [Abstract][Full Text] [Related]
8. The gut-liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19.
Piglionica M; Cariello M; Moschetta A
Curr Opin Pharmacol; 2018 Dec; 43():93-98. PubMed ID: 30223181
[TBL] [Abstract][Full Text] [Related]
9. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis.
Jia W; Xie G; Jia W
Nat Rev Gastroenterol Hepatol; 2018 Feb; 15(2):111-128. PubMed ID: 29018272
[TBL] [Abstract][Full Text] [Related]
10. The gut microbiota at the intersection of bile acids and intestinal carcinogenesis: An old story, yet mesmerizing.
Liu T; Song X; Khan S; Li Y; Guo Z; Li C; Wang S; Dong W; Liu W; Wang B; Cao H
Int J Cancer; 2020 Apr; 146(7):1780-1790. PubMed ID: 31291465
[TBL] [Abstract][Full Text] [Related]
11. Bisphenol A induced hepatic steatosis by disturbing bile acid metabolism and FXR/TGR5 signaling pathways via remodeling the gut microbiota in CD-1 mice.
Hong T; Zou J; He Y; Zhang H; Liu H; Mai H; Yang J; Cao Z; Chen X; Yao J; Feng D
Sci Total Environ; 2023 Sep; 889():164307. PubMed ID: 37211107
[TBL] [Abstract][Full Text] [Related]
12. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice.
Zheng X; Huang F; Zhao A; Lei S; Zhang Y; Xie G; Chen T; Qu C; Rajani C; Dong B; Li D; Jia W
BMC Biol; 2017 Dec; 15(1):120. PubMed ID: 29241453
[TBL] [Abstract][Full Text] [Related]
13. Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer.
Tsuei J; Chau T; Mills D; Wan YJ
Exp Biol Med (Maywood); 2014 Nov; 239(11):1489-504. PubMed ID: 24951470
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota.
Chen ML; Yi L; Zhang Y; Zhou X; Ran L; Yang J; Zhu JD; Zhang QY; Mi MT
mBio; 2016 Apr; 7(2):e02210-15. PubMed ID: 27048804
[TBL] [Abstract][Full Text] [Related]
15. Gut-liver axis-mediated mechanism of liver cancer: A special focus on the role of gut microbiota.
Ohtani N; Hara E
Cancer Sci; 2021 Nov; 112(11):4433-4443. PubMed ID: 34533882
[TBL] [Abstract][Full Text] [Related]
16. Sex-dependent effects on gut microbiota regulate hepatic carcinogenic outcomes.
Xie G; Wang X; Zhao A; Yan J; Chen W; Jiang R; Ji J; Huang F; Zhang Y; Lei S; Ge K; Zheng X; Rajani C; Alegado RA; Liu J; Liu P; Nicholson J; Jia W
Sci Rep; 2017 Mar; 7():45232. PubMed ID: 28345673
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiota-bile acid-intestinal Farnesoid X receptor signaling axis orchestrates cadmium-induced liver injury.
Liu Y; Kang W; Liu S; Li J; Liu J; Chen X; Gan F; Huang K
Sci Total Environ; 2022 Nov; 849():157861. PubMed ID: 35934034
[TBL] [Abstract][Full Text] [Related]
18. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
[TBL] [Abstract][Full Text] [Related]
19. Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation.
Sheng L; Jena PK; Hu Y; Liu HX; Nagar N; Kalanetra KM; French SW; French SW; Mills DA; Wan YY
J Pathol; 2017 Dec; 243(4):431-441. PubMed ID: 28892150
[TBL] [Abstract][Full Text] [Related]
20. Bile Acid Physiology.
Di Ciaula A; Garruti G; Lunardi Baccetto R; Molina-Molina E; Bonfrate L; Wang DQ; Portincasa P
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s4-s14. PubMed ID: 29080336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
